These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 18188748)
1. Smokeless tobacco reduction: preliminary study of tobacco-free snuff versus no snuff. Hatsukami DK; Ebbert JO; Edmonds A; Li C; Lin H; Le C; Hecht SS Nicotine Tob Res; 2008 Jan; 10(1):77-85. PubMed ID: 18188748 [TBL] [Abstract][Full Text] [Related]
2. Preliminary study on reducing oral moist snuff use. Hatsukami DK; Edmonds A; Schulte S; Jensen J; Le CT; Losey L; Carmella SG; Hecht SS Drug Alcohol Depend; 2003 May; 70(2):215-20. PubMed ID: 12732415 [TBL] [Abstract][Full Text] [Related]
3. Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings. Flanagan CA; Koller KR; Wolfe AW; Thomas TK; Benowitz NL; Renner CC; Hughes C; Hatsukami DK; Bronars C; Murphy NJ; Day G; Decker PA; Patten CA Nicotine Tob Res; 2016 Nov; 18(11):2162-2168. PubMed ID: 27190400 [TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of the nicotine lozenge and tobacco-free snuff for smokeless tobacco reduction. Ebbert JO; Severson HH; Croghan IT; Danaher BG; Schroeder DR Addict Behav; 2013 May; 38(5):2140-5. PubMed ID: 23454876 [TBL] [Abstract][Full Text] [Related]
5. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Hecht SS; Carmella SG; Murphy SE; Riley WT; Le C; Luo X; Mooney M; Hatsukami DK Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1567-72. PubMed ID: 17684130 [TBL] [Abstract][Full Text] [Related]
6. Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia. Kresty LA; Carmella SG; Borukhova A; Akerkar SA; Gopalakrishnan R; Harris RE; Stoner GD; Hecht SS Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):521-5. PubMed ID: 8827356 [TBL] [Abstract][Full Text] [Related]
7. Smokeless tobacco brand switching: a means to reduce toxicant exposure? Hatsukami DK; Ebbert JO; Anderson A; Lin H; Le C; Hecht SS Drug Alcohol Depend; 2007 Mar; 87(2-3):217-24. PubMed ID: 16996230 [TBL] [Abstract][Full Text] [Related]
9. Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. Hecht SS; Carmella SG; Ye M; Le KA; Jensen JA; Zimmerman CL; Hatsukami DK Cancer Res; 2002 Jan; 62(1):129-34. PubMed ID: 11782369 [TBL] [Abstract][Full Text] [Related]
10. Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. Hecht SS; Murphy SE; Carmella SG; Zimmerman CL; Losey L; Kramarczuk I; Roe MR; Puumala SS; Li YS; Le C; Jensen J; Hatsukami DK J Natl Cancer Inst; 2004 Jan; 96(2):107-15. PubMed ID: 14734700 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. Hatsukami DK; Lemmonds C; Zhang Y; Murphy SE; Le C; Carmella SG; Hecht SS J Natl Cancer Inst; 2004 Jun; 96(11):844-52. PubMed ID: 15173268 [TBL] [Abstract][Full Text] [Related]
12. Uptake and metabolism of carcinogenic levels of tobacco-specific nitrosamines by Sudanese snuff dippers. Murphy SE; Carmella SG; Idris AM; Hoffmann D Cancer Epidemiol Biomarkers Prev; 1994; 3(5):423-8. PubMed ID: 7920210 [TBL] [Abstract][Full Text] [Related]
13. The inside scoop on the stuff called snuff: an interview study of 94 adult male smokeless tobacco users. Severson HH; Eakin EG; Lichtenstein E; Stevens VJ J Subst Abuse; 1990; 2(1):77-85. PubMed ID: 2136105 [TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching. Hatsukami DK; Severson H; Anderson A; Vogel RI; Jensen J; Broadbent B; Murphy SE; Carmella S; Hecht SS Tob Control; 2016 May; 25(3):267-74. PubMed ID: 25991608 [TBL] [Abstract][Full Text] [Related]
15. Metabolism of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone to its biomarker total NNAL in smokeless tobacco users. Hecht SS; Carmella SG; Stepanov I; Jensen J; Anderson A; Hatsukami DK Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):732-5. PubMed ID: 18349296 [TBL] [Abstract][Full Text] [Related]
16. Urine 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol and cotinine in Alaska native postpartum women and neonates comparing smokers and smokeless tobacco users. Benowitz NL; Flanagan CA; Thomas TK; Koller KR; Wolfe AW; Renner CC; Hughes C; Decker PA; Hatsukami DK; Murphy NJ; Patten C Int J Circumpolar Health; 2018 Dec; 77(1):1528125. PubMed ID: 30325719 [TBL] [Abstract][Full Text] [Related]
17. Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention. Ebbert JO; Edmonds A; Luo X; Jensen J; Hatsukami DK Nicotine Tob Res; 2010 Aug; 12(8):823-7. PubMed ID: 20525780 [TBL] [Abstract][Full Text] [Related]
18. [Determination of 4-(methylnirosamino) -4-(3-pyridyl)-1-butanol (NNA) in urine of pregnant women by means of LC/MS/MS]. Florek E; Piekoszewski W; Lechowicz W; Szymańska A; Kornacka MK Przegl Lek; 2006; 63(10):926-31. PubMed ID: 17288186 [TBL] [Abstract][Full Text] [Related]
19. Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. Mendoza-Baumgart MI; Tulunay OE; Hecht SS; Zhang Y; Murphy S; Le C; Jensen J; Hatsukami DK Nicotine Tob Res; 2007 Dec; 9(12):1309-23. PubMed ID: 18058349 [TBL] [Abstract][Full Text] [Related]
20. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Stepanov I; Hecht SS Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):885-91. PubMed ID: 15824160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]